La Jolla Pharmaceutical Co. (LJPC) Trading Down 6.5%
La Jolla Pharmaceutical Co. (NASDAQ:LJPC) shares fell 6.5% on Wednesday . The stock traded as low as $17.60 and last traded at $17.82, with a volume of 74,280 shares trading hands. The stock had previously closed at $19.05.
Several brokerages recently weighed in on LJPC. Zacks Investment Research cut La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, June 15th. Lake Street Capital began coverage on La Jolla Pharmaceutical in a research note on Tuesday, May 24th. They set a “buy” rating and a $25.00 target price for the company. Jefferies Group reaffirmed a “buy” rating on shares of La Jolla Pharmaceutical in a research note on Wednesday, June 8th. Finally, SunTrust Banks Inc. began coverage on La Jolla Pharmaceutical in a research note on Wednesday, June 22nd. They set a “buy” rating and a $30.00 target price for the company. Seven investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of $38.83.
The company’s market capitalization is $326.75 million. The company’s 50 day moving average is $17.32 and its 200 day moving average is $17.71.
La Jolla Pharmaceutical (NASDAQ:LJPC) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.99) by $0.09. On average, analysts anticipate that La Jolla Pharmaceutical Co. will post ($3.76) EPS for the current year.
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.